{"id":812059,"date":"2025-02-12T08:47:43","date_gmt":"2025-02-12T13:47:43","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-secures-additional-u-s-patent-for-zunveyl-benzgalantamine-in-the-treatment-of-mild-to-moderate-alzheimers-disease\/"},"modified":"2025-02-12T08:47:43","modified_gmt":"2025-02-12T13:47:43","slug":"alpha-cognition-secures-additional-u-s-patent-for-zunveyl-benzgalantamine-in-the-treatment-of-mild-to-moderate-alzheimers-disease","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-secures-additional-u-s-patent-for-zunveyl-benzgalantamine-in-the-treatment-of-mild-to-moderate-alzheimers-disease\/","title":{"rendered":"Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer\u2019s disease"},"content":{"rendered":"

<\/p>\n

Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer\u2019s disease<\/b><\/p>\n

VANCOUVER–(BUSINESS WIRE<\/a>)–Alpha Cognition Inc. (NASDAQ: ACOG) <\/b>(\u201cAlpha Cognition\u201d (ACI), or the \u201cCompany\u201d), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent titled \u201cCoated Tablets for pH-Dependent Release of Benzgalantamine.\u201d<\/b><\/p>\n

\nThis newly issued patent strengthens Alpha Cognition\u2019s intellectual property portfolio by covering the composition of tablet formulations of benzgalantamine, further reinforcing the Company\u2019s existing patent protections. With this approval, ZUNVEYL has patent protection in the United States through 2044, supporting the Company\u2019s long-term growth strategy as it prepares for commercialization.<\/p>\n

\n\u201cThis patent approval underscores the innovative nature of ZUNVEYL and enhances our ability to deliver a differentiated treatment option for patients with mild to moderate Alzheimer\u2019s disease,\u201d said Michael McFadden, CEO of Alpha Cognition. \u201cThe timing of this milestone is significant, as it coincides with our planned U.S. launch of ZUNVEYL this quarter. With extended patent protection, we are well-positioned to maximize the potential of ZUNVEYL and continue advancing solutions for those affected by Alzheimer\u2019s.\u201d<\/p>\n

\nZUNVEYL represents a novel approach to symptomatic Alzheimer\u2019s treatment, designed to improve patient outcomes through optimized drug delivery. ZUNVEYL will be available by prescription in pharmacies nationwide in Q1 2025.<\/p>\n

About Alpha Cognition Inc.<\/b><\/p>\n

\nAlpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer\u2019s disease and Cognitive Impairment with mild Traumatic Brain Injury (\u201cmTBI\u201d), for which there are currently no approved treatment options.<\/p>\n

\nFor more information, please visit www.alphacognition.com<\/a>.<\/p>\n

Forward-looking Statements<\/b><\/p>\n

\nThis news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward\u2010looking statement that reflects the Company\u2019s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward\u2010looking statements by the words \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cobjective,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ctarget,\u201d \u201cseek,\u201d \u201ccontemplate,\u201d \u201ccontinue\u201d and \u201congoing,\u201d or the negative of these terms, or other comparable terminology intended to identify statements about the future. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital to implement our plans to commercialize ZUNVEYL, risks regarding the efficacy and tolerability of ZUNVEYL, risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL, risks related to the Company\u2019s intellectual property in relation to ZUNVEYL, risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL, risks related to product liability and other risks as described in the Company\u2019s filings with Canadian securities regulatory authorities and available at www.sedar.com<\/a> and the Company\u2019s filings with the United States Securities and Exchange Commission (the \u201cSEC\u201d), including those risk factors under the heading \u201cRisk Factors\u201d in the Company\u2019s Form S-1\/A registration statement as filed with the SEC on November 6, 2024 and available at www.sec.gov<\/a>. These forward\u2010looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward\u2010looking statements for any reason, even if new information becomes available in the future, except as required by law.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250212688224\/en\/<\/a><\/span><\/p>\n

\nFor further information:
\n
Michael McFadden, CEO
\n
Tel: 1-858-344-4375
\n
info@alphacognition.com
\n<\/a>
https:\/\/www.alphacognition.com\/<\/a><\/p>\n

KEYWORDS:<\/b> North America Canada<\/p>\n

INDUSTRY KEYWORDS:<\/b> Neurology Biotechnology Pharmaceutical Public Relations\/Investor Relations General Health Health Mental Health Communications<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer\u2019s disease VANCOUVER–(BUSINESS WIRE)–Alpha Cognition Inc. (NASDAQ: ACOG) (\u201cAlpha Cognition\u201d (ACI), or the \u201cCompany\u201d), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent titled \u201cCoated Tablets for pH-Dependent Release of Benzgalantamine.\u201d This newly issued patent strengthens Alpha Cognition\u2019s intellectual property portfolio by covering the composition of tablet formulations of benzgalantamine, further reinforcing the Company\u2019s existing patent protections. With this approval, ZUNVEYL has patent protection in the United States through 2044, supporting the Company\u2019s long-term growth strategy as it prepares for commercialization. \u201cThis patent approval underscores the innovative … <\/p>\n

Continue reading “Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer\u2019s disease”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-812059","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAlpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer\u2019s disease - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-secures-additional-u-s-patent-for-zunveyl-benzgalantamine-in-the-treatment-of-mild-to-moderate-alzheimers-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer\u2019s disease - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer\u2019s disease VANCOUVER–(BUSINESS WIRE)–Alpha Cognition Inc. (NASDAQ: ACOG) (\u201cAlpha Cognition\u201d (ACI), or the \u201cCompany\u201d), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent titled \u201cCoated Tablets for pH-Dependent Release of Benzgalantamine.\u201d This newly issued patent strengthens Alpha Cognition\u2019s intellectual property portfolio by covering the composition of tablet formulations of benzgalantamine, further reinforcing the Company\u2019s existing patent protections. With this approval, ZUNVEYL has patent protection in the United States through 2044, supporting the Company\u2019s long-term growth strategy as it prepares for commercialization. \u201cThis patent approval underscores the innovative … Continue reading "Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer\u2019s disease"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-secures-additional-u-s-patent-for-zunveyl-benzgalantamine-in-the-treatment-of-mild-to-moderate-alzheimers-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-12T13:47:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250212688224r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-secures-additional-u-s-patent-for-zunveyl-benzgalantamine-in-the-treatment-of-mild-to-moderate-alzheimers-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-secures-additional-u-s-patent-for-zunveyl-benzgalantamine-in-the-treatment-of-mild-to-moderate-alzheimers-disease\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer\u2019s disease\",\"datePublished\":\"2025-02-12T13:47:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-secures-additional-u-s-patent-for-zunveyl-benzgalantamine-in-the-treatment-of-mild-to-moderate-alzheimers-disease\\\/\"},\"wordCount\":678,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-secures-additional-u-s-patent-for-zunveyl-benzgalantamine-in-the-treatment-of-mild-to-moderate-alzheimers-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250212688224r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-secures-additional-u-s-patent-for-zunveyl-benzgalantamine-in-the-treatment-of-mild-to-moderate-alzheimers-disease\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-secures-additional-u-s-patent-for-zunveyl-benzgalantamine-in-the-treatment-of-mild-to-moderate-alzheimers-disease\\\/\",\"name\":\"Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer\u2019s disease - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-secures-additional-u-s-patent-for-zunveyl-benzgalantamine-in-the-treatment-of-mild-to-moderate-alzheimers-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-secures-additional-u-s-patent-for-zunveyl-benzgalantamine-in-the-treatment-of-mild-to-moderate-alzheimers-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250212688224r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-02-12T13:47:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-secures-additional-u-s-patent-for-zunveyl-benzgalantamine-in-the-treatment-of-mild-to-moderate-alzheimers-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-secures-additional-u-s-patent-for-zunveyl-benzgalantamine-in-the-treatment-of-mild-to-moderate-alzheimers-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-secures-additional-u-s-patent-for-zunveyl-benzgalantamine-in-the-treatment-of-mild-to-moderate-alzheimers-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250212688224r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250212688224r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-secures-additional-u-s-patent-for-zunveyl-benzgalantamine-in-the-treatment-of-mild-to-moderate-alzheimers-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer\u2019s disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer\u2019s disease - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-secures-additional-u-s-patent-for-zunveyl-benzgalantamine-in-the-treatment-of-mild-to-moderate-alzheimers-disease\/","og_locale":"en_US","og_type":"article","og_title":"Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer\u2019s disease - Market Newsdesk","og_description":"Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer\u2019s disease VANCOUVER–(BUSINESS WIRE)–Alpha Cognition Inc. (NASDAQ: ACOG) (\u201cAlpha Cognition\u201d (ACI), or the \u201cCompany\u201d), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent titled \u201cCoated Tablets for pH-Dependent Release of Benzgalantamine.\u201d This newly issued patent strengthens Alpha Cognition\u2019s intellectual property portfolio by covering the composition of tablet formulations of benzgalantamine, further reinforcing the Company\u2019s existing patent protections. With this approval, ZUNVEYL has patent protection in the United States through 2044, supporting the Company\u2019s long-term growth strategy as it prepares for commercialization. \u201cThis patent approval underscores the innovative … Continue reading \"Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer\u2019s disease\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-secures-additional-u-s-patent-for-zunveyl-benzgalantamine-in-the-treatment-of-mild-to-moderate-alzheimers-disease\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-12T13:47:43+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250212688224r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-secures-additional-u-s-patent-for-zunveyl-benzgalantamine-in-the-treatment-of-mild-to-moderate-alzheimers-disease\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-secures-additional-u-s-patent-for-zunveyl-benzgalantamine-in-the-treatment-of-mild-to-moderate-alzheimers-disease\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer\u2019s disease","datePublished":"2025-02-12T13:47:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-secures-additional-u-s-patent-for-zunveyl-benzgalantamine-in-the-treatment-of-mild-to-moderate-alzheimers-disease\/"},"wordCount":678,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-secures-additional-u-s-patent-for-zunveyl-benzgalantamine-in-the-treatment-of-mild-to-moderate-alzheimers-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250212688224r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-secures-additional-u-s-patent-for-zunveyl-benzgalantamine-in-the-treatment-of-mild-to-moderate-alzheimers-disease\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-secures-additional-u-s-patent-for-zunveyl-benzgalantamine-in-the-treatment-of-mild-to-moderate-alzheimers-disease\/","name":"Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer\u2019s disease - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-secures-additional-u-s-patent-for-zunveyl-benzgalantamine-in-the-treatment-of-mild-to-moderate-alzheimers-disease\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-secures-additional-u-s-patent-for-zunveyl-benzgalantamine-in-the-treatment-of-mild-to-moderate-alzheimers-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250212688224r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-02-12T13:47:43+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-secures-additional-u-s-patent-for-zunveyl-benzgalantamine-in-the-treatment-of-mild-to-moderate-alzheimers-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-secures-additional-u-s-patent-for-zunveyl-benzgalantamine-in-the-treatment-of-mild-to-moderate-alzheimers-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-secures-additional-u-s-patent-for-zunveyl-benzgalantamine-in-the-treatment-of-mild-to-moderate-alzheimers-disease\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250212688224r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250212688224r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-secures-additional-u-s-patent-for-zunveyl-benzgalantamine-in-the-treatment-of-mild-to-moderate-alzheimers-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer\u2019s disease"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/812059","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=812059"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/812059\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=812059"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=812059"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=812059"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}